伊马替尼为什么不能治愈慢性髓性白血病？
Why doesn't imatinib cure chronic myeloid leukemia?
机构信息
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
出版信息
Oncologist. 2010;15(2):182-6. doi: 10.1634/theoncologist.2009-0297. Epub 2010 Feb 2.
Abstract
Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib. In this review we analyze the biology behind the failure of imatinib to fully eradicate CML. We review evidence that indicates that the leukemic stem cell for CML is inherently resistant to imatinib, and that imatinib treatment itself may enhance this resistance.
摘要
甲磺酸伊马替尼改变了慢性髓性白血病（CML）的治疗方法。绝大多数患者获得血液学缓解，疾病进展的概率较低。然而，伊马替尼很少能治愈 CML，目前的建议是终身用伊马替尼治疗。在这篇综述中，我们分析了伊马替尼未能完全消除 CML 的生物学基础。我们回顾了表明 CML 的白血病干细胞天生对伊马替尼具有耐药性的证据，并且伊马替尼治疗本身可能增强这种耐药性。
相似文献
1
Why doesn't imatinib cure chronic myeloid leukemia?伊马替尼为什么不能治愈慢性髓性白血病？
Oncologist. 2010;15(2):182-6. doi: 10.1634/theoncologist.2009-0297. Epub 2010 Feb 2.
2
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.由BCR-ABL调节的凋亡微小RNA表达与慢性粒细胞白血病进展及伊马替尼耐药相关。
Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11.
3
4
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.新型酪氨酸激酶抑制剂PD166326在慢性髓性白血病小鼠模型中具有比甲磺酸伊马替尼更强的抗白血病活性。
Blood. 2005 May 15;105(10):3995-4003. doi: 10.1182/blood-2004-09-3534. Epub 2005 Jan 18.
5
Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.尼洛替尼与伊马替尼联合治疗可改善伊马替尼耐药急变期 CML 的疗效。
Acta Haematol. 2012;127(3):152-5. doi: 10.1159/000333107. Epub 2012 Jan 27.
6
Targeted chronic myeloid leukemia therapy: Seeking a cure.靶向慢性髓性白血病治疗：寻求治愈方法。
Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. doi: 10.2146/ajhp070482.
7
Imatinib mesylate in the treatment of chronic myelogenous leukemia.甲磺酸伊马替尼治疗慢性粒细胞白血病。
Int J Hematol. 2004 Jun;79(5):411-9. doi: 10.1532/ijh97.04054.
8
Mechanisms and implications of imatinib resistance mutations in BCR-ABL.BCR-ABL中伊马替尼耐药突变的机制及影响
Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006.
9
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.对接受甲磺酸伊马替尼治疗的慢性粒细胞白血病（CML）患者的BCR-ABL转录本进行连续监测。
Med Oncol. 2004;21(4):349-58. doi: 10.1385/MO:21:4:349.
10
Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?端粒酶在慢性期慢性髓性白血病、疾病进展和伊马替尼耐药中起作用吗？
Leuk Lymphoma. 2008 Jun;49(6):1022-3. doi: 10.1080/10428190802074635.
引用本文的文献
1
Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring.慢性髓性白血病的代谢组学分析与生物分析：确定治疗反应和疾病监测的生物标志物
Metabolites. 2025 Jun 6;15(6):376. doi: 10.3390/metabo15060376.
2
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition.I13通过直接抑制BCR-ABL，克服了慢性髓性白血病中由T315I突变介导的耐药性。
Front Pharmacol. 2023 Apr 12;14:1183052. doi: 10.3389/fphar.2023.1183052. eCollection 2023.
3
Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.治疗肺动脉高压的新型实验性疗法
J Exp Pharmacol. 2021 Aug 17;13:817-857. doi: 10.2147/JEP.S236743. eCollection 2021.
4
A Broad Overview of Signaling in -Negative Classic Myeloproliferative Neoplasms.阴性经典型骨髓增殖性肿瘤中的信号传导概述
Cancers (Basel). 2021 Feb 26;13(5):984. doi: 10.3390/cancers13050984.
5
The Search for Disease-Modifying Therapies in Pulmonary Hypertension.肺动脉高压中疾病修饰疗法的探索。
J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):334-354. doi: 10.1177/1074248419829172. Epub 2019 Feb 17.
6
FZD7 regulates BMSCs-mediated protection of CML cells.FZD7调节骨髓间充质干细胞介导的对慢性粒细胞白血病细胞的保护作用。
Oncotarget. 2016 Feb 2;7(5):6175-87. doi: 10.18632/oncotarget.6742.
7
Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.新型药物氯化两面针碱通过c-Myc-微小RNA轴诱导慢性粒细胞白血病细胞红系分化和凋亡。
PLoS One. 2015 Feb 3;10(2):e0116880. doi: 10.1371/journal.pone.0116880. eCollection 2015.
8
Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.基因组定量实时PCR证实，在慢性髓性白血病中，超过30%基于mRNA的定量逆转录PCR结果为阴性的样本存在残留病阳性。
Oncoscience. 2014 Jul 23;1(7):510-21. doi: 10.18632/oncoscience.65. eCollection 2014.
9
Pathways in pulmonary arterial hypertension: the future is here.肺动脉高压中的通路：未来已来。
Eur Respir Rev. 2012 Dec 1;21(126):321-7. doi: 10.1183/09059180.00004812.
10
Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.进一步表型分析脐带血、动员外周血和慢性髓性白血病患者中分离的原始谱系 CD34+CD38-CD90+CD45RA-造血干/祖细胞亚群。
Blood Cancer J. 2011 Sep;1(9):e36. doi: 10.1038/bcj.2011.35. Epub 2011 Sep 30.
本文引用的文献
1
A progenitor cell origin of myeloid malignancies.髓系恶性肿瘤的祖细胞起源。
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16616-21. doi: 10.1073/pnas.0908107106. Epub 2009 Sep 21.
2
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.蛋白酶体抑制可导致白血病消退，并部分通过调节叉头框肿瘤抑制因子消除BCR-ABL诱导的细胞凋亡逃避。
Cancer Res. 2009 Aug 15;69(16):6546-55. doi: 10.1158/0008-5472.CAN-09-0605. Epub 2009 Aug 4.
3
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.白血病起始细胞在伊马替尼反应性骨髓增殖性疾病条件性敲入模型中的持续性
Cancer Cell. 2009 Aug 4;16(2):137-48. doi: 10.1016/j.ccr.2009.06.007.
4
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.蛋白酶体抑制剂与甲磺酸伊马替尼在慢性髓性白血病中的协同作用。
PLoS One. 2009 Jul 16;4(7):e6257. doi: 10.1371/journal.pone.0006257.
5
Stem-cell driven cancer: "hands-off" regulation of cancer development.干细胞驱动的癌症：对癌症发展的“不干预”调控
Cell Cycle. 2009 May 1;8(9):1314-8. doi: 10.4161/cc.8.9.8217. Epub 2009 May 18.
6
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.慢性期慢性粒细胞白血病中的造血干细胞具有类似于正常髓系祖细胞的转录谱特征，并反映出静止状态的丧失。
Leukemia. 2009 May;23(5):892-9. doi: 10.1038/leu.2008.392. Epub 2009 Jan 22.
7
Translation of the Philadelphia chromosome into therapy for CML.将费城染色体转化为慢性粒细胞白血病的治疗方法。
Blood. 2008 Dec 15;112(13):4808-17. doi: 10.1182/blood-2008-07-077958.
8
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.针对伊马替尼耐药慢性髓性白血病的新兴干细胞概念：对该疾病生物学、管理及治疗的影响
Br J Haematol. 2008 Jul;142(3):361-78. doi: 10.1111/j.1365-2141.2008.07197.x. Epub 2008 Jun 5.
9
Chronic myeloid leukemia stem cells.慢性髓系白血病干细胞
J Clin Oncol. 2008 Jun 10;26(17):2911-5. doi: 10.1200/JCO.2008.17.5745.
10
PML targeting eradicates quiescent leukaemia-initiating cells.靶向多瘤病毒相关进行性多灶性白质脑病可根除静止的白血病起始细胞。
Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11.
Zotero 插件